Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
162
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

346
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
346
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Inhaled Medications01:23

Inhaled Medications

220
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
220

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Miniaturized Neural Networks for Deploying Fully Closed Loop Insulin Delivery Systems: A Pilot Study Featuring Flexible Meal Announcement Options.

Journal of diabetes science and technology·2025
Same author

Toward Personalized Decision Support Systems for Type 1 Diabetes: Integrating Psychobehavioral Factors and Glycemic Control.

Journal of diabetes science and technology·2025
Same author

Metabolic Models, in Silico Trials, and Algorithms.

Journal of diabetes science and technology·2025
Same author

Evolution of the Artificial Pancreas: Components and Integration-CGMs, Insulin, and AP Systems.

Journal of diabetes science and technology·2025
Same author

Early Stages of Automated Insulin Delivery.

Journal of diabetes science and technology·2025
Same author

Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems.

Journal of diabetes science and technology·2025
Same journal

Continuous Glucose Monitoring and Early Dysglycemia: Toward an Emerging Stage Preceding Prediabetes.

Journal of diabetes science and technology·2026
Same journal

A Pilot Study on Disposal Practices and Environmental Awareness of Insulin-Related Devices Among People With Diabetes.

Journal of diabetes science and technology·2026
Same journal

Quality of In-Use Insulin Under Real-World Storage Conditions in Mwanza, Tanzania.

Journal of diabetes science and technology·2026
Same journal

Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening.

Journal of diabetes science and technology·2026
Same journal

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same journal

AI-Driven Diabetes Care and Its Relevance in the Philippine Context: Opportunities and Persistent Digital Barriers.

Journal of diabetes science and technology·2026
See all related articles

Related Experiment Video

Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.6K

A Performance-Based Adaptation Index for Automated Insulin Delivery Systems.

Jenny L Diaz C1,2, Patricio Colmegna1,3, Elliot Pryor1

  • 1Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA, USA.

Journal of Diabetes Science and Technology
|February 6, 2025
PubMed
Summary
This summary is machine-generated.

The Performance-Based Adaptation Index (PAI) automatically adjusts automated insulin delivery (AID) aggressiveness using continuous glucose monitoring (CGM) data. This tool enhances glycemic control for individuals with type 1 diabetes.

Keywords:
artificial pancreasautomated insulin deliveryfully automated closed loopglucose controlinsulin therapy adaptationtype 1 diabetes

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.0K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.4K

Related Experiment Videos

Last Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.6K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.0K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.4K

Area of Science:

  • Biomedical Engineering
  • Endocrinology
  • Diabetes Technology

Background:

  • Automated insulin delivery (AID) systems require personalized tuning for optimal performance.
  • Individual insulin needs vary, necessitating adaptive algorithms.
  • Continuous glucose monitoring (CGM) provides key data for algorithm adjustment.

Purpose of the Study:

  • To introduce the Performance-Based Adaptation Index (PAI) for automatic adjustment of AID system aggressiveness.
  • To enable AID systems to adapt to individual user needs and varying glycemic conditions.
  • To improve glycemic outcomes in type 1 diabetes management.

Main Methods:

  • Developed PAI integrating hypoglycemia and hyperglycemia CGM metrics into a single index.
  • Proposed two computation methods for PAI: time in range (TIR) and glycemic risk indices.
  • Assessed PAI feasibility in-silico using the UVA/Padova Type 1 Diabetes Simulator with a model predictive control (MPC) algorithm.

Main Results:

  • PAI adjustment significantly improved Time in Range (TIR) from 35.1% to 71.8% in a conservative scenario.
  • PAI reduced hypoglycemia exposure (TBR from 2.6% to 1.4%) in an aggressive scenario.
  • PAI demonstrated safe and effective automatic tuning of the UVA-MPC controller in simulations.

Conclusions:

  • PAI enables automatic tuning of AID controllers for improved glycemic control.
  • Simulations show PAI can achieve TIR >70% in various physiological states.
  • Clinical validation is recommended to confirm in-silico findings.